Diagnostics to deal with new diseases

Maria Brytting at the Swedish Institute for Infectious Disease Control, SMI, will share her experiences from April 2009 when the new influenza A virus, H1N1, was first reported globally.

Hur stoppa vaccinskräcken?

Chatt inspirerade till bättre molnberäkningar

En grupp forskare har byggt en ny teknik för molnberäkningar. Istället för fråga-svar principen bygger programmet på omvänd kommunikation mellan server och dator. - Webbtjänster används mycket i biovetenskaper, säger en av forskarna, Ola Spjuth.

With their hands on the legal levers

It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.

The winner of the race

She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.

Ny produkt hittar antibiotika i mat

Under året kommer MIP Technologies att lansera flera produkter för att upptäcka små doser av bland annat antibiotikaliknande ämnen i mat.

Ny direktör till danska Opus

Det danska projektet för att optimera välbefinnandet hos danska barn genom förändrade kostvanor, får en ny direktör.

Utmärkelse till KIs rektor

"För sin enastående inverkan på vetenskapen och förmåga att inspirera andra" uppmärksammas Karolinska Institutets rektor Harriet Wallberg-Henriksson vid en ceremoni i San Francisco idag.

Hon är ny på Stockholm Science City

Stockholm Science Citys projekt Tools of Science har fått en ny projektansvarig.

En kvarts miljard till diabetesforskning

Ett Europeiskt konsortium ska särskilt studera komplikationer vid diabetes. Flera svenska lärosäten ingår i gruppen som får en svensk koordinator.

Storsatsning på ren luft

Vårdrelaterade infektioner gör att efterfrågan stiger på teknik för ren luft. Toul Meditech expanderar starkt och nyanställer tre produktspecialister.

Vetenskapsverktyg växer

Tools of Science omfattar inte längre bara Stockholm-Uppsalaregionen.

Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Faster sales but less profits for Probi

The probiotic company increases its turnover, and the net results are twice as large as last year.

Swedish top scientists to EMBO

Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.

Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

First ever study of human stem cell treatment

The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.

Test if you carry the fat virus

In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.

Athera signs production partnership

The companys novel cardiovascular product will be manufactured in Germany.

Teams up with leading dermatologist

Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.

Go ahead for leg wound study

Tripep starts a phase II-study of their wound healing joint venture project.

Re-painting the big pig-ture

Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.

Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.

Lundbeck divests companies

The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.